Publications
221
Citations
1,796
Est. group size
~53
Recurring co-author estimate
Active years
12
Publishing since 2015
Casey Cosgrove's research focuses on gynecologic cancers, particularly endometrial and ovarian cancer, examining tumor genetics, molecular classification, and treatment outcomes. Much of the work involves large clinical trials and real-world patient registries to understand how molecular and genetic features relate to survival, treatment response, and disparities between patient groups. The research also explores emerging therapies such as immunotherapy and antibody-drug conjugates in gynecologic cancers.
Publication output has grown substantially over the past decade, rising from single digits per year before 2021 to over 40 publications annually in 2024-2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Abstract 1144: Tumor genomic features and postsurgical ctDNA status in patients with stage I-IV uterine cancer
Cancer Research · 2026
- Profiling the immune repertoire in a phase II trial of niraparib and dostarlimab in recurrent or persistent uterine serous carcinomas
Gynecologic Oncology · 2026
- Characterization of the tumor microenvironment in endometrial cancer
Gynecologic Oncology · 2026
- Serum biomarkers of prognosis and resistance in advanced high-grade serous carcinoma patients undergoing primary debulking surgery and adjuvant chemotherapy
Gynecologic Oncology · 2026
- Overall survival by histologic subtype within the molecular classification of endometrial cancer
Gynecologic Oncology · 2026
- Tumoral, clinical, and environmental factors, including microbiome, immune cell infiltration and air pollution, associated with endometrial cancer recurrence
Gynecologic Oncology · 2026
- POLE mutation analysis, molecular characterization, and associations with survival outcomes: Ancillary analysis of GOG-0258
Gynecologic Oncology · 2026
- Final overall survival analysis among patients with folate receptor alpha-positive, platinum-resistant ovarian cancer treated with mirvetuximab soravtansine versus investigator's choice chemotherapy in phase II MIRASOL (GOG-3045/ENGOT-ov55) study
Gynecologic Oncology · 2025
- Dual Immune Checkpoint Blockade in Microsatellite Instability-High Cancers—Effective, but for Whom and When?
JAMA Oncology · 2025
- A working group report from the 2024 National Cancer Institute / Gynecologic Cancer Steering Committee endometrial cancer clinical trials planning meeting: refining the approach to endometrial cancer in the immunotherapy era
JNCI Journal of the National Cancer Institute · 2025
- Quality-Adjusted Time Without Symptoms Of Disease Progression Or Toxicity Analysis Of Mirvetuximab Soravtansine Versus Investigator’s Choice Of Chemotherapy In Folate Receptor-Alpha Positive, Platinum-Resistant Ovarian Cancer
International Journal of Gynecological Cancer · 2025
- Endometrial cancer somatic testing practice patterns among gynecologic oncologists
Gynecologic Oncology · 2025
- Molecular classification and association with survival outcomes in high-intermediate and high-risk early-stage endometrial cancers: Ancillary analysis of GOG-0249
Gynecologic Oncology · 2025
- 1164P Efficacy and safety of balstilimab with or without zalfrelimab in recurrent cervical cancer: Results from the global phase II RaPiDs trial
Annals of Oncology · 2025
- Disease progression, survival, and molecular disparities in Black and White patients with endometrioid endometrial carcinoma in real-world registries and GOG/NRG oncology randomized phase III clinical trials
Gynecologic Oncology · 2024
- Gynecologic Oncology×121
- Cancer Research×12
- SSRN Electronic Journal×10
- Gynecologic Oncology Reports×8
- Journal of Clinical Oncology×7
- Paulina Haight
Medicine · The Ohio State University
- Adrian A. Suarez
Medicine · The Ohio State University
- David E. Cohn
Medicine · The Ohio State University
- Lisa M. Landrum
Medicine · Indiana University
- Courtney Riedinger
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile